Literature DB >> 26490987

MicroRNA-101 polymorphisms and risk of head and neck squamous cell carcinoma in a Chinese population.

Limin Miao1, Lihua Wang2, Hua Yuan1, Dong Hang2, Longbiao Zhu1, Jiangbo Du2, Xun Zhu2, Bing Li1, Ruixia Wang1, Hongxia Ma3,4, Ning Chen5,6.   

Abstract

MicroRNAs (miRNAs) play important roles in regulation of gene expressions and likely have involvement in cancer susceptibility and disease progression. MicroRNA-101 (miR-101) has been well established as a tumor suppressor, and aberrant expression of miR-101 levels has been previously reported in different malignancies including head and neck squamous cell carcinoma (HNSCC). However, the role of single nucleotide polymorphisms (SNPs) of miR-101 in the susceptibility to HNSCC remains unclear. In this study, we genotyped 11 selected SNPs of the miR-101 genes (including miR-101-1 and miR-101-2) in a case-control study including 576 HNSCC cases and 1552 cancer-free controls. For the main effect analysis, none of the 11 selected SNPs was associated with HNSCC risk. However, in the stratification analysis by tumor sites, rs578481 and rs705509 in pri-miR-101-1 were significantly associated with risk of oral squamous cell carcinoma (OSCC) (rs578481: adjusted odds ratio (OR) = 1.19, 95 % confidence interval (CI) 1.01-1.39, P = 0.036; rs705509: adjusted OR = 0.85, 95 % CI 0.73-0.98, P = 0.030). Furthermore, combined analysis of the two SNPs revealed that subjects carrying the risk alleles of rs578481 and rs705509 had increased risk of OSCC in a dose-response manner (P trend = 0.022). Compared with subjects carrying "0-2" risk alleles, subjects carrying "3-4" risk alleles presented a 1.38-fold increased risk of OSCC. In conclusion, our findings suggested that the SNPs rs578481 and rs705509 locating in pri-miR-101-1 may play a role in genetic susceptibility to OSCC, which may improve our understanding of the potential contribution of miRNA SNPs to cancer pathogenesis.

Entities:  

Keywords:  Association; Head and neck squamous cell carcinoma; MicroRNA; Polymorphism; Susceptibility

Mesh:

Substances:

Year:  2015        PMID: 26490987     DOI: 10.1007/s13277-015-4249-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

Review 1.  The functions of animal microRNAs.

Authors:  Victor Ambros
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

2.  Prognostic role of microRNA polymorphisms in patients with advanced esophageal squamous cell carcinoma receiving platinum-based chemotherapy.

Authors:  Chaohui Wu; Minjie Li; Chao Hu; Hongbing Duan
Journal:  Cancer Chemother Pharmacol       Date:  2013-11-28       Impact factor: 3.333

3.  MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf¹/cip¹).

Authors:  Assaad Semaan; Aamer M Qazi; Shelly Seward; Sreedhar Chamala; Christopher S Bryant; Sanjeev Kumar; Robert Morris; Christopher P Steffes; David L Bouwman; Adnan R Munkarah; Donald W Weaver; Scott A Gruber; Ramesh B Batchu
Journal:  Pharm Res       Date:  2011-08-05       Impact factor: 4.200

4.  MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met.

Authors:  Zhenghui Hu; Yiwei Lin; Hong Chen; Yeqing Mao; Jian Wu; Yi Zhu; Xin Xu; Xianglai Xu; Shiqi Li; Xiangyi Zheng; Liping Xie
Journal:  Biochem Biophys Res Commun       Date:  2013-04-22       Impact factor: 3.575

5.  A common variant in pre-miR-146 is associated with coronary artery disease risk and its mature miRNA expression.

Authors:  Xing-dong Xiong; Miook Cho; Xiu-ping Cai; Jie Cheng; Xia Jing; Jin-ming Cen; Xinguang Liu; Xi-li Yang; Yousin Suh
Journal:  Mutat Res       Date:  2014-01-19       Impact factor: 2.433

6.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

7.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

Review 8.  A review of risk factors and genetic alterations in head and neck carcinogenesis and implications for current and future approaches to treatment.

Authors:  Loredana G Marcu; E Yeoh
Journal:  J Cancer Res Clin Oncol       Date:  2009-07-30       Impact factor: 4.553

9.  The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma.

Authors:  R Banerjee; R-S Mani; N Russo; C S Scanlon; A Tsodikov; X Jing; Q Cao; N Palanisamy; T Metwally; R C Inglehart; S Tomlins; C Bradford; T Carey; G Wolf; S Kalyana-Sundaram; A M Chinnaiyan; S Varambally; N J D'Silva
Journal:  Oncogene       Date:  2011-05-02       Impact factor: 9.867

10.  miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells.

Authors:  Ye Lei; Bin Li; Shiyu Tong; Lin Qi; Xiheng Hu; Yunbo Cui; Zengbo Li; Wei He; Xiongbing Zu; Zhi Wang; Minfeng Chen
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

View more
  2 in total

1.  MiRNA-101 inhibits oral squamous-cell carcinoma growth and metastasis by targeting zinc finger E-box binding homeobox 1.

Authors:  Baolei Wu; Delin Lei; Lei Wang; Xinjie Yang; Sen Jia; Zihui Yang; Chun Shan; Xi Yang; Chenping Zhang; Bin Lu
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

2.  miRNA-101 Targets TGF-βR1 to Retard the Progression of Oral Squamous Cell Carcinoma.

Authors:  Yong Wang; Rui-Zhi Jia; Shu Diao; Jun He; Li Jia
Journal:  Oncol Res       Date:  2019-12-12       Impact factor: 5.574

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.